Issued by National Institute on Drug Abuse (NIDA)
Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
Release Date: January 11, 2023
Estimated Publication Date of Funding Opportunity Announcement: May 09, 2023
First Estimated Application Due Date: November 05, 2023
Earliest Estimated Award Date: July 01, 2024
Earliest Estimated Start Date: July 10, 2024
The National Institute on Drug Abuse intends to re-issue the Funding Opportunity Announcement (FOA) PAR-19-282, “Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)”.
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
The FOA is expected to be published in Spring 2023 with an expected application due date in Fall 2023.
This FOA will utilize the R61/R33 activity code. Details of the planned FOA are provided below.
Research Initiative Details
This FOA continues NIDA’s interest in exploratory clinical neuroscience research on substance use disorders (SUD) to support clinical research applications that are in early and conceptual stages of project development and focus on understanding the neurobiological mechanisms underlying SUD, including fundamental brain function relevant to substance use (see PAR-19-282 for details).
The FOA will employ the R61/R33 Phased Innovation Award activity code. Support will be provided for up to 5 years, which will include initial support of up to 2 years of the R61 phase, followed by up to 3 years of support for the R33 phase, upon successfully meeting R61 milestones. Preliminary data will not be required; however, applicants may include preliminary data if they are available.
The reissued FOA will continue to seek new and resubmission applications.
For the full announcement, click here.